Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic's Activa

This article was originally published in The Gray Sheet

Executive Summary

Parkinson's disease control therapy system debuts in Europe following receipt of a CE mark, Medtronic reports April 27. The implantable neurostimulator is being marketed in Europe for use in stimulating the globus pallidus or subthalamic regions of the brain to control all major symptoms of Parkinson's disease, including rigidity, bradykinesia/akinesia, postural instability, and tremor. The Activa received FDA approval in July 1997 for stimulation of the thalamus to treat essential tremor and tremor associated with Parkinson's disease ("The Gray Sheet" Aug. 11, 1997, p. 5). Clinical evaluation in the U.S. for the expanded use is underway
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT009991

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel